ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2024
hsa_circ_0000520 Serves as a Prognostic Biomarker for Colorectal Cancer and Promotes in the Disease Progression.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nocturnal Melatonin Deficiency in Colorectal Cancer: Independent Predictive Value Beyond Sleep Quality.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Colorectal cancer (CRC) constitutes one of the prevalent malignancies within the gastrointestinal tract and serves as a primary contributor to cancer-related mortalities. This investigation sought to investigate the expression and prognostic significance of hsa_circ_0000520 in CRC and to evaluate its impact on the onset of CRC. Materials and Methods: The levels of hsa_circ_0000520 were measured via quantitative real-time polymerase chain reaction (qRTPCR). To delve into the mechanism through which circ_0000520 impacts CRC and to assess the cellular behavior of CRC cells, a series of experiments including the CCK-8, transwell assay, flow cytometer assay, cell cloning formation, dual-luciferase reporter assay, and bioinformatics method were performed. Results: The expression levels of hsa_circ_0000520 were markedly elevated in CRC cells and tissue specimens, and this elevation was correlated with a low survival rate. hsa_circ_0000520 affected CRC cell function via the miR-542-3p/MYH9 axis, thus exacerbating cancer progression. Conclusion: hsa_circ_0000520 functions as a predictive biomarker for the prognosis of CRC and participates in its progression. hsa_ circ_0000520 emerges as a new treatment strategy for CRC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.